A phase I expansion study to evaluate the efficacy and safety of Altiratinib in patients with actionable MET and TRK genomic alterations.
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2016
At a glance
- Drugs Altiratinib (Primary)
- Indications Cancer
- Focus Therapeutic Use
- 07 Jan 2016 New trial record
- 05 Jan 2016 According to Deciphera Pharmaceuticals media release, the phase I expansion trials of altiratinib in patients with actionable MET and TRK genomic alterations are expected to start early in 2016.